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The idea of dedicating a special issue of the journal to
explore the challenges posed by late presentation of HIV
infection is based upon several considerations. In 2010, after
three decades since the beginning of the AIDS epidemics,
still 15–38% of patients with HIV infection continue to be
diagnosed late. As expected, late presenters demonstrate a
less favourable clinical course, with reduced or incomplete
treatment response, more rapid clinical progression, and
higher risk of mortality. In addition, they generate a
considerable and avoidable resource burden to the healthcare
system. Furthermore, undiagnosed HIV-infected individ-
uals contribute disproportionatelly to the spread of HIV
disease. The latter has become even more important now
that antiretroviral therapy has been conclusively shown to
decrease HIV transmision by greater than 90%. As a result,
expanding and even normalizing HIV testing is increassingly
recognized by international guidelines to be a key public
health priority, in order to improve access to care, to allow
an earlier antiretroviral treatment initiation, and ultimately
to decrease HIV-related morbidity and mortality as well as
HIV transmission.
This issue contains five key papers. L. Saganic and col-
leagues report a persistent unacceptably high proportion of
late diagnoses of HIV in Washington state between 2000 and
2009, despite the implementation of CDC recommendations
for HIV testing in the last five years. The conclusion is
that HIV screening procedures, largely dependent on an
individual’s perception of his/her HIV risk, have failed; in
fact, people who are more likely to be diagnosed late with
HIV usually do not consider themselves as “risk categories”
and have poor access to HIV testing. Consistent with several
other publications, also in this study, heterosexuals, women,
elderly people, foreign-born individuals, and people residing
in a rural area showed higher risk of late HIV diagnosis.
Interestingly, two diﬀerent measures of late presentation are
compared: the lab-based measure (CD4+ T-cell count at
presentation <350 cells/mmc) and the time-based one (AIDS
event within 12 months of initial HIV diagnosis). Both
measures underline the same risk factors for late HIV testing.
The laboratory-based definition, however, appears to be the
more clinically relevant one due to the fact that it reflects the
importance of the CD4+ T-cell count for determining the
optimal time to initiated antiretroviral therapy; although the
application of this definitionmay be limited in some settings,
this should improve as the quality of laboratory systems
improves in the future. Nevertheless, the contemporary use
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of both measures may oﬀer a consistent assessment of the
problem of late presentation.
Also in the study conducted by K. Buchacz and col-
leagues, the proportion of HIV-positive patients who first
present a CD4+ T-cell count <350 cells/mmc at first presen-
tation to care was extremely high (58%) consistent with the
previous paper. K. Buchacz analyzed data from participants
in the HIV Outpatient Study (HOPS) from eight USA cities,
includingWashington, over the same time period considered
by L. Saganic (2000–2009). Again, similar risk factors for
Late Presentation were identified (heterosexual transmission,
older age, and nonwhite ethnicity). Interestingly, the median
CD4+ T-cell count at HIV diagnosis remained stable over
time, with only a trend towards higher CD4+ T-cell counts
in those infected via heterosexual sex and people attending
public facilities. Taken together, these studies provide a
strong rationale for the normalization of HIV testing.
One of the limitations of many analyses of late pre-
sentation is that definitions do not generally incorporate
information on duration of infection prior to diagnosis
(which is often unknown). The CD4+ T-cell count at
diagnosis is therefore used as a surrogate for this. To get
around this problem, P. Sobrino-Vegas et al. used a multiple
imputation method to estimate the probable date of HIV
seroconversion for all patients in their Spanish cohort (some
of whom were known seroconverters); late diagnosis was
then defined as an interval of greater than 4.19 years between
the time of seroconversion and the time of first testing. This
group, which comprised 34% of the cohort, were more often
male, older, and of non-Spanish origin. Using this definition,
39% of newly diagnosed subjects had presented late; these
individuals were more commonly intravenous drug users.
Use of this diﬀerent approach to the estimation of late
diagnosis underlines the importance of further strengthening
HIV screening procedures.
From an immunological perspective, F. Bai et al. reported
that late presenters tend to be characterized by CD127
down-regulation on CD4+ T-cells and immune activation;
as these patients are in an advanced stage of infection
and are at higher risk of disease progression and of poor
immune reconstitution, when they start antiretroviral ther-
apy, peripheral T lymphocytes immune phenotypes could be
proposed as adjunctive markers to complement CD4+ count
when attempting to identify andmonitor late presenters. The
distinctive immunological patterns seen in late presenters
were similar regardless of the definition of late HIV diagnosis
that was used: CD4+ T-cell count <350 cell/mmc (late pre-
sentation), CD4+ T-cell count <200 cells/mmc (Advanced
HIV disease), or AIDS defining condition at presentation
regardless of the patient’s CD4+ T-cell counts (AIDS presen-
tation).
Finally, H. B. Krentz and M. J. Gill report a similarly high
proportion of new patients who present late (59%) and
describe the significantly higher costs incurred by this group,
most notably when considering inpatient costs and any costs
incurred during the first year after entry to care. In particular,
the economic burden associated with late presentation
remained elevated after the first year, at twice that of patients
presenting with a CD4+ T-cell count >350 cells/mm3.
As underlined by these works, late presentation for HIV
remains a key unresolved challenge in HIV/AIDS with seri-
ous adverse consequences at the individual and societal
levels. The tools are available to fully address this problem.
Implementation science and operations research initiatives
are urgently needed to better define the best strategies to
eliminate late presentation. This will be an essential step to
control HIV morbidity, mortality, and transmission.
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